P
28.10
0.34 (1.22%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Palvella Therapeutics, Inc. | 看跌 | - |
AIStockmoo 评分
0.6
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.63 |
|
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella’s lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 17.50% |
| 机构持股比例 | 37.21% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Adams Street Partners Llc | 31 Dec 2024 | 409,666 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 50.00 (Scotiabank, 77.94%) | 购买 |
| 中 | 44.50 (58.36%) | |
| 低 | 38.00 (HC Wainwright & Co., 35.23%) | 购买 |
| 平均值 | 43.50 (54.80%) | |
| 总计 | 6 购买 | |
| 平均价格@调整类型 | 23.57 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 01 Apr 2025 | 38.00 (35.23%) | 购买 | 28.10 |
| 11 Feb 2025 | 38.00 (35.23%) | 购买 | 16.15 | |
| Stifel | 26 Mar 2025 | 45.00 (60.14%) | 购买 | 27.93 |
| Jones Trading | 25 Mar 2025 | 45.00 (60.14%) | 购买 | 27.27 |
| Scotiabank | 07 Mar 2025 | 50.00 (77.94%) | 购买 | 24.55 |
| Canaccord Genuity | 26 Feb 2025 | 39.00 (38.79%) | 购买 | 18.80 |
| 20 Feb 2025 | 39.00 (38.79%) | 购买 | 19.00 | |
| TD Cowen | 05 Feb 2025 | 44.00 (56.58%) | 购买 | 14.76 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合